Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biogen to Spin Off Hemophilia Unit, Focus on Neurodegenerative Drugs

By Drug Discovery Trends Editor | May 4, 2016

Credit: Chitose Suzuki. Biogen​Biogen announced Tuesday the company plans to spin off its hemophilia drug business as a publicly traded company, and instead concentrate on developing treatments for neurodegenerative diseases, primarily multiple sclerosis (MS).

This new company will include Biogen’s hemophilia drugs, Eloctate and Alprolix for hemophilia A and B, which had combined global sales of $554.2 million in sales last year — and a combined $640 million during the 12 months ending March 31. In 2015, these hemophilia treatments accounted for 5 percent of Biogen’s revenue.

The planned spinoff will be completed later this year or in 2017, Biogen said. It’s expected to be accomplished through a distribution of shares of the new company to Biogen stockholders in an intended tax-free transaction.

Spinning off its hemophilia drug business will allow Biogen the opportunity to focus on its MS drugs (Tecfidera is its bestselling MS treatment). The Cambridge, Mass.-based biotech will also focus its research-and-development efforts on neurodegenerative treatments such as Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and neuropathic pain.

The planned spinoff has surprised analysts, though, who anticipated that Biogen would sell its hemophilia drug business for as much as $4 billion to $6 billion, and acquire other assets, reported The Wall Street Journal.

Biogen, however, views the spinoff as creating two profitable companies, enabling the new company “to operate independently with a management team dedicated to providing therapies to people living with hemophilia,” said George Scangos, Ph.D., Biogen’s chief executive officer, in a statement.

But analysts are speculating the move could be strategic, particularly since the multiple sclerosis drug business faces competition. RBC Capital analyst Michael Yee said in a note to clients, that splitting the company in two smaller ones could make Biogen an acquisition target.

Last month, Biogen reported its first-quarter profit grew 18 percent, in part to increased sales of its multiple sclerosis drug Tecfidera.

The new, publicly traded company will continue to collaborate on the development and commercialization of Eloctate and Alprolix with Swedish Orphan Biovitrum AB. Biogen’s executive vice president, John G. Cox, will be the CEO of the new company, based in the Boston area.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE